Similar articles for PMID: 28546332

Year	Number of Results
2008	1
2009	1
2011	1
2013	2
2015	6
2016	21
2017	21
2018	33
2019	43
2020	59
2021	72
2022	55
2023	31
2024	0

1

Establishing ¹⁷⁷Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer.

Fendler WP, Stuparu AD, Evans-Axelsson S, Lückerath K, Wei L, Kim W, Poddar S, Said J, Radu CG, Eiber M, Czernin J, Slavik R, Herrmann K. Fendler WP, et al. J Nucl Med. 2017 Nov;58(11):1786-1792. doi: 10.2967/jnumed.117.193359. Epub 2017 May 25. J Nucl Med. 2017. PMID: 28546332 Free PMC article.

2

First-in-human study of ¹⁷⁷Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, Li F, Jacobson O, Niu G, Zhu Z, Chen X. Zang J, et al. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):148-158. doi: 10.1007/s00259-018-4096-y. Epub 2018 Aug 8. Eur J Nucl Med Mol Imaging. 2019. PMID: 30090965 Free PMC article.

3

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.

Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ. Baum RP, et al. J Nucl Med. 2016 Jul;57(7):1006-13. doi: 10.2967/jnumed.115.168443. Epub 2016 Jan 21. J Nucl Med. 2016. PMID: 26795286 Free article.

4

Outcome and safety of rechallenge [¹⁷⁷Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.

Yordanova A, Linden P, Hauser S, Meisenheimer M, Kürpig S, Feldmann G, Gaertner FC, Essler M, Ahmadzadehfar H. Yordanova A, et al. Eur J Nucl Med Mol Imaging. 2019 May;46(5):1073-1080. doi: 10.1007/s00259-018-4222-x. Epub 2018 Nov 24. Eur J Nucl Med Mol Imaging. 2019. PMID: 30474706

5

The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.

Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, Eisenhut M, Kübler W, Holland-Letz T, Giesel FL, Mier W, Kopka K, Haberkorn U. Afshar-Oromieh A, et al. J Nucl Med. 2015 Nov;56(11):1697-705. doi: 10.2967/jnumed.115.161299. Epub 2015 Aug 20. J Nucl Med. 2015. PMID: 26294298 Free article.

6

²²⁵Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.

Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, Davis C, Mahapane J, Corbett C, Vorster M, Morgenstern A. Sathekge M, et al. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):129-138. doi: 10.1007/s00259-018-4167-0. Epub 2018 Sep 19. Eur J Nucl Med Mol Imaging. 2019. PMID: 30232539 Free PMC article.

7

Preparation of ¹⁷⁷Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House.

Guleria M, Amirdhanayagam J, Sarma HD, Rallapeta RP, Krishnamohan VS, Nimmagadda A, Ravi P, Patri S, Kalawat T, Das T. Guleria M, et al. Biomed Res Int. 2021 Nov 20;2021:1555712. doi: 10.1155/2021/1555712. eCollection 2021. Biomed Res Int. 2021. PMID: 34845436 Free PMC article.

8

Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors.

Wang Z, Tian R, Niu G, Ma Y, Lang L, Szajek LP, Kiesewetter DO, Jacobson O, Chen X. Wang Z, et al. Bioconjug Chem. 2018 Sep 19;29(9):3213-3221. doi: 10.1021/acs.bioconjchem.8b00556. Epub 2018 Aug 22. Bioconjug Chem. 2018. PMID: 30105912

9

Efficacy and safety of ²²⁵Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients.

Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C. Yadav MP, et al. Theranostics. 2020 Jul 23;10(20):9364-9377. doi: 10.7150/thno.48107. eCollection 2020. Theranostics. 2020. PMID: 32802197 Free PMC article.

10

Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.

Kabasakal L, AbuQbeitah M, Aygün A, Yeyin N, Ocak M, Demirci E, Toklu T. Kabasakal L, et al. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1976-83. doi: 10.1007/s00259-015-3125-3. Epub 2015 Jul 31. Eur J Nucl Med Mol Imaging. 2015. PMID: 26227531

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

281 results

Results by year